
Companion preprint to USPTO provisional patent application. Applies a 12-step computational pipeline to GSE161470 (Hu et al., human left ventricular scRNA-seq, 9,803 cells, DCM vs. normal). Reports cell-type-resolved differential expression, ChEMBL bioactivity screening (17,793 candidates), and PubChem novelty filtering identifying LESTAURTINIB, R-406, FORETINIB, CERDULATINIB, DASATINIB, and CHEMBL5653589 as novel repurposing candidates targeting the CSF1R/SYK macrophage inflammatory axis and cytoskeletal remodeling pathways. Authors: Glen Charles Ritschel (Ritschel Research, Tega Cay SC) and Claude (Anthropic, San Francisco CA). CC BY 4.0.
DASATINIB, SCN9A, drug repurposing, left ventricle, heart failure, CSF1R, computational pharmacology, NOVEL_ALL, dilated cardiomyopathy, LESTAURTINIB, scRNA-seq, SYK, CHEMBL5653589, single-cell transcriptomics, sodium channel
DASATINIB, SCN9A, drug repurposing, left ventricle, heart failure, CSF1R, computational pharmacology, NOVEL_ALL, dilated cardiomyopathy, LESTAURTINIB, scRNA-seq, SYK, CHEMBL5653589, single-cell transcriptomics, sodium channel
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 0 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
